HALOFENATE (BioDeep_00000649983)
代谢物信息卡片
HALOFENATE
化学式: C19H17ClF3NO4 (415.0798)
中文名称: 卤芬酯
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(=O)NCCOC(=O)C(C1=CC=C(C=C1)Cl)OC2=CC=CC(=C2)C(F)(F)F
InChI: InChI=1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)
描述信息
D018501 - Antirheumatic Agents > D006074 - Gout Suppressants > D014528 - Uricosuric Agents
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents
C26170 - Protective Agent > C921 - Uricosuric Agent
D009676 - Noxae > D000963 - Antimetabolites
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- KEGGdrug: D04411
- PubChem: 33584
- ChEMBL: CHEMBL456071
- MeSH: Halofenate
- CAS: 24136-24-1
- CAS: 24091-96-1
- CAS: 26718-25-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Theresa M Thieme, Ramona Steri, Ewgenij Proschak, Alexander Paulke, Gisbert Schneider, Manfred Schubert-Zsilavecz. Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator.
Bioorganic & medicinal chemistry letters.
2010 Apr; 20(8):2469-73. doi:
10.1016/j.bmcl.2010.03.008. [PMID: 20307981] - Tamara Allen, Fang Zhang, Shonna A Moodie, L Edward Clemens, Aaron Smith, Francine Gregoire, Andrea Bell, George E O Muscat, Thomas A Gustafson. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
Diabetes.
2006 Sep; 55(9):2523-33. doi:
10.2337/db06-0618. [PMID: 16936200] - E A Kohl, J A Magner, S T Persellin, G M Vaughan, D J Kudzma, S J Friedberg. Improved control of non-insulin-dependent diabetes mellitus by combined halofenate and chlorpropamide therapy.
Diabetes care.
1984 Jan; 7(1):19-24. doi:
10.2337/diacare.7.1.19. [PMID: 6368149] - E B Feldman, F B Gluck, A C Carter. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
Journal of clinical pharmacology.
1978 May; 18(5-6):241-8. doi:
10.1002/j.1552-4604.1978.tb02442.x. [PMID: 346616] - O Kuntzen, F J Hehl, E Walter, R Zimmermann. [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)].
Arzneimittel-Forschung.
1978; 28(12):2349-52. doi:
NULL. [PMID: 227420] - Huzoor-Akbar, N G Ardlie. The effect of halofenate--free acid on aggregation--the release reaction, coagulant activity, and lipid metabolism of human platelets.
Thrombosis and haemostasis.
1977 Oct; 38(3):612-9. doi:
10.1055/s-0038-1651876. [PMID: 579507] - F E Karch, W M Wardell, M Dambly, A Gringeri. Effect of halofenate on the serum binding of phenytoin.
British journal of clinical pharmacology.
1977 Oct; 4(5):625-6. doi:
10.1111/j.1365-2125.1977.tb00798.x. [PMID: 911611] - D R Bassett, W M Mikkelsen, R B Buckingham, W D Block, M Sidiq, A Shakibai, R DiGaetano, L L Liou. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
Clinical pharmacology and therapeutics.
1977 Sep; 22(3):340-51. doi:
10.1002/cpt1977223340. [PMID: 330079] - D J Kudzma, S J Friedberg. Potentiation of hypoglycemic effect of chlorpropamide and phenfromin by halofenate.
Diabetes.
1977 Apr; 26(4):291-5. doi:
10.2337/diab.26.4.291. [PMID: 321288] - L H Krut, H C Seftel, B I Joffe. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
1977 Mar; 51(11):348-52. doi:
NULL. [PMID: 323994] - L R Mandel. Studies on the mechanism of action of halofenate.
Lipids.
1977 Jan; 12(1):34-43. doi:
10.1007/bf02532969. [PMID: 319318] - G M Fanelli. Urate excretion.
Annual review of medicine.
1977; 28(?):349-54. doi:
10.1146/annurev.me.28.020177.002025. [PMID: 324366] - L E Anthony, A L Jones. Influence of 2-acetoamidoethyl (p-chloro-phenyl) (m-trifluoromethylphenoxy) acetate (halofenate) on hepatic drug metabolism in retired breeder rats.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.).
1977 Jan; 154(1):142-5. doi:
10.3181/00379727-154-39623a. [PMID: 402655] - C A Dujovne, D L Azarnoff, P Pentikainen, C Manion, A Hurwitz, K Hassanein. A two-year crossover therapeutic trial with halofenate and clofibrate.
The American journal of the medical sciences.
1976 Nov; 272(3):277-84. doi:
10.1097/00000441-197611000-00005. [PMID: 797258] - P J Davis, F B Davis, R D Utiger, S F Kulaga. Changes in serum thyrotropin (TSH) in man during halofenate administration.
The Journal of clinical endocrinology and metabolism.
1976 Oct; 43(4):873-81. doi:
10.1210/jcem-43-4-873. [PMID: 824301] - E D Rees, R D Hamilton, I F Kanner, S Wasson, T Hearn. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
Atherosclerosis.
1976 Sep; 24(3):537-46. doi:
10.1016/0021-9150(76)90146-5. [PMID: 788722] - R W Colman, J S Bennett, J F Sheridan, R A Cooper, S J Shattil. Halofenate: a potent inhibitor of normal and hypersensitive platelets.
The Journal of laboratory and clinical medicine.
1976 Aug; 88(2):282-91. doi:
". [PMID: 956686] - F E Karch, J P Morgan, N P Kubasik, H E Sine. Effect of halofenate on serum thyroid hormone determinations in vitro.
The Journal of clinical endocrinology and metabolism.
1976 Jul; 43(1):26-31. doi:
10.1210/jcem-43-1-26. [PMID: 820706] - D H Huffman, D L Azarnoff, D W Shoeman, C A Dujovne. The interaction between halofenate and propranolol.
Clinical pharmacology and therapeutics.
1976 Jun; 19(6):807-12. doi:
10.1002/cpt1976196807. [PMID: 773588] - W D Wosilait, P Nagy. The distribution of halofenate in plasma: a comparative analysis using Scatchard vs. stepwise association constants.
Research communications in chemical pathology and pharmacology.
1976 May; 14(1):75-81. doi:
NULL. [PMID: 935655] - D H Minsker, P T Jordan, P Kling, A MacMillan, H B Hucker. The effect of halofenate or halofenate free acid on human, rat and guinea pig platelet aggregation.
Thrombosis and haemostasis.
1976 Apr; 35(2):358-63. doi:
. [PMID: 989636] - C A Dujovne, D L Azarnoff, D H Huffman, P Pentikäinen, A Hurwitz, D W Shoeman. One-year trials with halofenate, clofibrate, and placebo.
Clinical pharmacology and therapeutics.
1976 Mar; 19(3):352-9. doi:
10.1002/cpt1976193352. [PMID: 177242] - R J Cenedella, W G Crouthamel. Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.
Journal of lipid research.
1976 Mar; 17(2):156-66. doi:
10.1016/s0022-2275(20)37001-2. [PMID: 1270931] - D Yeshurun, A M Gotto. Drug treatment of hyperlipidemia.
The American journal of medicine.
1976 Mar; 60(3):379-96. doi:
10.1016/0002-9343(76)90755-5. [PMID: 1258886] - R P Eaton, R Oase, D S Schade. Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of theraphy?.
Metabolism: clinical and experimental.
1976 Mar; 25(3):245-9. doi:
10.1016/0026-0495(76)90082-2. [PMID: 1250161] - C Keller, G Wolfram, N Zöllner. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
Arzneimittel-Forschung.
1976; 26(12):2221-4. doi:
NULL. [PMID: 798591] - A K Jain, J R Ryan, F G McMahon. Potentiation of hypoglycemic effect of sulfonylureas by halofenate.
The New England journal of medicine.
1975 Dec; 293(25):1283-6. doi:
10.1056/nejm197512182932503. [PMID: 171574] - W S Aronow, M D Vicario, K Moorthy, J King, M Vawter, N P Papageorge's. Long-term efficacy of halofenate on serum triglyceride levels.
Current therapeutic research, clinical and experimental.
1975 Dec; 18(6):855-61. doi:
NULL. [PMID: 813950] - M Weintraub, P F Griner. Alterations in the effects of warfarin in dogs by halofenate: an influence upon the kinetics of prothrombin.
Thrombosis et diathesis haemorrhagica.
1975 Nov; 34(2):445-54. doi:
10.1055/s-0038-1651403. [PMID: 1198407] - R Bluestone, D Campion, J R Klinenberg. Halofenate. Its selection and trial as a primary uricosuric agent.
Arthritis and rheumatism.
1975 Nov; 18(6 Suppl):859-62. doi:
10.1002/art.1780180732. [PMID: 1106434] - J R Ryan. The metabolic spectrum of halofenate.
International journal of clinical pharmacology and biopharmacy.
1975 Jul; 12(1-2):239-43. doi:
NULL. [PMID: 51838] - G J Schapel, K D Edwards. Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
The Journal of pharmacology and experimental therapeutics.
1975 Jul; 194(1):274-84. doi:
. [PMID: 1171221] - D N Brindley, M Bowley. Drugs affecting the synthesis of glycerides and phospholipids in rat liver. The effects of clofibrate, halofenate, fenfluramine, amphetamine, cinchocaine, chlorpromazine, demethylimipramine, mepyramine and some of their derivatives.
The Biochemical journal.
1975 Jun; 148(3):461-9. doi:
10.1042/bj1480461. [PMID: 1200988] - H J Lisch, J Patsch, S Sailer, H Braunsteiner. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
Atherosclerosis.
1975 May; 21(3):391-9. doi:
10.1016/0021-9150(75)90051-9. [PMID: 1148032] - M D Greenspan, J I Germershausen, R Mackow. Effect of halofenate and clofibrate on lipid synthesis in rat adipocytes.
Biochimica et biophysica acta.
1975 Feb; 380(2):190-8. doi:
10.1016/0005-2760(75)90005-3. [PMID: 1120140] - E S Vesell, G T Passananti. Anomalous results of studies on drug interaction in man. II. Halofenate (mk-185) and antipyrine, bishydroxycoumarin, and warfarin.
Pharmacology.
1975; 13(2):112-27. doi:
10.1159/000136892. [PMID: 49900] - W S Aronow, J Vangrow, J Pagano, M Khemka, M Vawter, N P Papageorge's. Long-term effect of halofenate on serum lipids.
Current therapeutic research, clinical and experimental.
1974 Sep; 16(9):897-903. doi:
NULL. [PMID: 4214664] - V Beaumont, J C Buxtorf, B Jacotot, J L Beaumont. Comparative study of several hypolipidemic agents related to clofibrate.
Atherosclerosis.
1974 Sep; 20(2):141-53. doi:
10.1016/0021-9150(74)90001-x. [PMID: 4369878] - J E Baer. Monitoring of plasma levels of a hypolipemic agent.
Clinical pharmacology and therapeutics.
1974 Jul; 16(1):272-3. doi:
10.1002/cpt1974161part2272. [PMID: 4843317] - A Gattereau, J Davignon, M Verdy, W Lewis. Halofenate versus clofibrate in the management of true diabetes insipidus.
Canadian Medical Association journal.
1974 Jun; 110(11):1275-77. doi:
. [PMID: 4834432] - J C Hutchison, W H Wilkinson. Halofenate: effectiveness of two dosage forms and two dose schedules.
Atherosclerosis.
1974 May; 19(3):417-28. doi:
10.1016/s0021-9150(74)80006-7. [PMID: 4133379] - W S Aronow, J S Vangrow, W H Nelson, J Pagano, N P Papageorge's, M Khursheed, P R Harding, M Khemka. Halofenate, serum lipids, and exercise performance in coronary heart disease.
Clinical pharmacology and therapeutics.
1974 Jan; 15(1):67-72. doi:
10.1002/cpt197415167. [PMID: 4587107] - P J Davis, B S Handwerger. Thyroid hormone binding in dog plasma.
Endocrinology.
1973 Dec; 93(6):1445-8. doi:
10.1210/endo-93-6-1445. [PMID: 4752895] - J E Fletcher, J D Ashbrook, A A Spector. Computer analysis of drug-protein binding data.
Annals of the New York Academy of Sciences.
1973 Nov; 226(?):69-81. doi:
10.1111/j.1749-6632.1973.tb20469.x. [PMID: 4520404] - A A Spector, E C Santos, J D Ashbrook, J E Fletcher. Influence of free fatty acid concentration on drug binding to plasma albumin.
Annals of the New York Academy of Sciences.
1973 Nov; 226(?):247-58. doi:
10.1111/j.1749-6632.1973.tb20486.x. [PMID: 4520396] - J C Hutchison, W H Wilkinson. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
Atherosclerosis.
1973 Nov; 18(3):353-62. doi:
10.1016/0021-9150(73)90065-8. [PMID: 4584481] - L H Schlosstein, I Kippen, M W Whitehouse, R Bluestone, H E Paulus, J R Klinenberg. Studies with some novel uricosuric agents and their metabolites: correlation between clinical activity and drug-induced displacement of urate from its albumin-binding sites.
The Journal of laboratory and clinical medicine.
1973 Sep; 82(3):412-8. doi:
NULL. [PMID: 4740876] - W S Aronow, P R Harding, M Khursheed, J S Vangrow, N P Papageorge's. Effect of halofenate on serum uric acid.
Clinical pharmacology and therapeutics.
1973 May; 14(3):371-3. doi:
10.1002/cpt1973143371. [PMID: 4572799] - W S Aronow, P R Harding, M Khursheed, J S Vangrow, N P Papageorge's, J Mays. Effect of halofenate on serum lipids.
Clinical pharmacology and therapeutics.
1973 May; 14(3):358-65. doi:
10.1002/cpt1973143358. [PMID: 4572798] - M D Greenspan, J I Germershausen. Effect of halofenate and clofibrate on growth and lipid synthesis in Saccharomyces cerevisiae.
Journal of bacteriology.
1973 Feb; 113(2):847-55. doi:
10.1128/jb.113.2.847-855.1973. [PMID: 4570609] - G B Bluhm, J M Riddle. Platelets and vascular disease in gout.
Seminars in arthritis and rheumatism.
1973; 2(4):355-66. doi:
10.1016/0049-0172(73)90023-1. [PMID: 4702575] - C Sirtori, R Fumagalli, R Paoletti. Hypolipidemic drugs.
Advances in experimental medicine and biology.
1973; 38(?):171-98. doi:
". [PMID: 4594063] - J E Baer. Role of drug metabolism in drug research and development: basic considerations.
Journal of pharmaceutical sciences.
1972 Oct; 61(10):1674-7. doi:
10.1002/jps.2600611039. [PMID: 4627330]
